Tech 5: Bitcoin Drops Below US$100,000, Micron Guidance Shakes Investors

Bitcoin surged early in the week before retracting below US$100,000, dampened by a hawkish rate cut from the US Federal Reserve that led to significant drops in both the crypto and stock markets. Meanwhile, the Nasdaq-100 (INDEXNASDAQ:NDX) welcomed three new companies, and artificial intelligence leader NVIDIA (NASDAQ:NVDA) lost ground to networking giant Broadcom (NASDAQ:AVGO). Find…

Read More

Stardust Power Acquires Site, Receives Key Permit And Receives Approval For Major Construction To Commence

Stardust Power Inc.(“the Company” or “Stardust Power”) (NASDAQ: SDST), an American developer of battery-grade lithium products, today announced the completion of the acquisition of its 66-acre site at the Southside Industrial Park in Muskogee, Oklahoma. This key acquisition marks another significant milestone as the Company prepares to commence construction on one of North America’s largest…

Read More

FALCO ANNOUNCES CLOSING OF BROKERED PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TSXV – FPC Falco Resources Ltd. (TSXV: FPC) (‘ Falco ‘ or the ‘ Corporation ‘) is pleased to announce the closing of its previously announced ‘best efforts’ brokered private placement (the ‘ Offering ‘) with Cantor Fitzgerald Canada…

Read More

Opawica Announces the Closing of Non-Brokered Private Placement

(TheNewswire) December 20th, 2024 Vancouver, B.C. TheNewswire – Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the ‘Company’ or ‘Opawica’), a Canadian mineral exploration company focused on precious and base metal projects, is pleased to announce that it has closed the recently announced private placement (December 17, 2024) of 4,330,00 Units for total aggregate…

Read More

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol…

Read More